Poor
Not Aligned
Patient Risk:
Medium
Summary
Most claims introduce elderly-specific dosing/counseling and toxicity mechanisms not supported by the provided FDA label excerpts. Only renal/hepatic impairment risk and dose reduction/discontinuation concepts are partially supported, and even those are partly overstated in the elderly-specific framing.
Category Scores
Accurate Statements
Patients with impaired renal function are at increased risk of methotrexate adverse reactions and dosage should be reduced or methotrexate discontinued as appropriate.
Label section 8.6 Renal Impairment: “Patients with renal impairment are at increased risk for methotrexate adverse reactions… Reduce the dosage or discontinue methotrexate tablets as appropriate.”
Patients with impaired liver function may be at increased risk of methotrexate adverse reactions and dosage should be reduced or methotrexate discontinued as appropriate.
Label section 8.7 Hepatic Impairment: “Patients with hepatic impairment may be at increased risk… Reduce the dosage or discontinue methotrexate tablets as appropriate.”
Unsupported Statements
The American College of Rheumatology recommends that elderly patients receive a lower starting dose of methotrexate, typically 7.5–10 mg per week.
No ACR recommendations or elderly-specific starting dose range are present in the provided label excerpts.
The American College of Rheumatology recommends that elderly patients gradually increase the methotrexate dose as needed and tolerated.
No ACR recommendations or elderly-specific titration guidance are present in the provided label excerpts.
Elderly patients may require a lower starting dose of methotrexate due to decreased liver and kidney function.
The provided label excerpts do not state that elderly patients require lower starting doses due to age-related decreased liver/kidney function.
Decreased liver and kidney function in elderly patients can lead to increased levels of methotrexate in the blood.
The provided label excerpts do not connect elderly age-related organ function decline to increased blood levels of methotrexate.
Healthcare providers must carefully monitor elderly patients' response to methotrexate and adjust the dosage as needed to minimize the risk of toxicity.
The provided label excerpts provide monitoring guidance for renal/hepatic impairment, but not an elderly-specific monitoring/adjustment requirement.
Potential risks associated with methotrexate use in elderly patients include increased risk of toxicity.
The provided geriatric section excerpt discusses lack of sufficient elderly study numbers and does not state elderly patients have increased toxicity risk.
Potential risks associated with methotrexate use in elderly patients include decreased liver and kidney function.
Hepatotoxicity and renal toxicity are discussed generally, but the provided excerpts do not state that elderly patients’ risks include decreased liver/kidney function as an elderly-specific risk.
Contradictions
Important Omissions
No FDA label-supported statement was provided in the AI claims about what the label specifies for elderly patients regarding dosing/response (the excerpt states only that there were insufficient numbers aged 65+ to determine differential response).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Elderly-specific dosing and mechanism claims are not supported by the provided label excerpts, which could mislead dosing practices. However, the impairment-specific risk/dose reduction concepts are partially aligned.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple elderly-specific recommendations and mechanistic causality statements (e.g., ACR guidance, elderly need for lower starting dose, increased blood levels) are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict statements to label-supported content: (1) acknowledge the label’s geriatric study limitation (insufficient subjects aged 65+ to determine different response), and (2) for renal/hepatic impairment, state increased risk of adverse reactions and that dosage may need reduction or discontinuation as appropriate with recommended monitoring—without asserting elderly-specific lower starting doses or blood-level mechanisms.